Mesoblast Limited (OTCMKTS:MEOBF – Get Free Report)’s share price dropped 8.8% during mid-day trading on Tuesday . The stock traded as low as $1.55 and last traded at $1.55. 135 shares were traded during trading, a decline of 94% from the average session volume of 2,171 shares. The stock had previously closed at $1.70.
Mesoblast Price Performance
The firm’s 50-day moving average price is $1.65 and its two-hundred day moving average price is $1.63.
Mesoblast Company Profile
Mesoblast Limited (OTCMKTS:MEOBF) is a global leader in regenerative medicine focused on the development and commercialization of innovative allogeneic cell therapies. The company’s proprietary platform harnesses mesenchymal lineage adult stem cells to address a range of inflammatory and immunological conditions. Mesoblast’s pipeline includes multiple late-stage and marketed products that target serious diseases with high unmet medical needs.
The company’s lead product, remestemcel-L (Ryvicor/Ryoncil), is under development for the treatment of steroid-refractory acute graft versus host disease in pediatric patients and has received conditional approval for certain indications in Japan.
Recommended Stories
- Five stocks we like better than Mesoblast
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.
